Extended Analysis for Leukemia/Lymphoma Treatment (EXALT)
A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients
Patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma harboring an activating genetic alteration (gene mutation, gene fusion) or drug-able biomarker / activated signal transduction pathway and resistant to any approved treatment modality will be eligible for this study.
The investigators aim to combine DNA sequencing-based molecular profiling with an ex vivo high-throughput drug screening strategy. For the latter method, viable cells are obtained from the individual patient's lymphoma or leukemia in order to determine i)the expression of relevant therapeutic target molecules and ii)the ex vivo response of the patient's cancer cells to a panel of agents with anticancer activity. In addition, analysis of tumor stroma cells will provide information about the differential target expression and cellular sensitivity aiming at the evaluation of a therapeutic safety window. Thereby, biological material will have to be accessed within 4 weeks before onset of individualized treatment (real-time biopsy). Bioinformatic data-management based on a Bayesian statistical approach will support individualized treatment decisions in this controlled clinical approach.
調査の概要
詳細な説明
Background and rationale for the trial Etiological concepts on cancer development, malignant growth and tumor propagation have led to the discovery of various molecular driver mechanisms. Based on these advances, medical oncology has started to enter an era of individualized medicine where treatment selection is becoming tailored to drug-able molecular pathways. This individualized treatment concept is mainly based on molecular and genetic characterization of the tumors including biomarker technology, which allow us to align the most appropriate treatment according to the patient's disease. Although there is a general acceptance towards such individualized approach thereby stratifying and subgrouping patients to improve the quality of clinical care in oncology, molecular profiling has just started to assist prediction of the drug's clinical benefit by identifying the most responsive patient subgroup. Recently, excellent demonstrations of the utility of prognostic and/or predictive biomarkers have emerged. Von Hoff and co-workers have recently demonstrated that molecular profiling of patients' tumors is an efficient approach to identify potential targets and select treatments for their treatment-refractory cancers(Von Hoff, Stephenson et al. 2010). Such a tailored treatment strategy revealed to be an effective approach to increase progression free survival (PFS), when compared to the patients' most recent standard treatment regimen. Another example for individualized treatment of patients is given by the recently published BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination), a prospective biomarker and biopsy driven trial in pretreated non-small cell lung cancer (NSCLC) patients (Kim, Herbst et al. 2011). By this Bayesian approach, the authors demonstrated that targeting individually analyzed molecules of the patient's tumor might represent an efficient therapeutic approach in the treatment of an incurable disease. While these examples suggest a benefit for individual tumor characterization for selection of a tailored treatment concept, currently novel targeted agents in the treatment of cancer are rather approved for a certain subtype of cancer, but not for patients based on the expression or activity of respective target lesions. Therefore, the need of an extension of clinical protocols focusing on molecular profile-based treatment decisions, rather than on anatomic cancer-subtypes is mandatory. Based on this concept the current protocol was designed. The investigators hypothesize that molecular profiling of a patient's tumor might not only predict treatment response, but also leads to an individualized treatment protocol resulting in clinical benefit for the individual patient. Therefore, this project aims to assess the feasibility of an individualized treatment concept for pre-defined patient's benefit.
Design, methodology, statistical considerations and organization The Medical University of Vienna will be clinical sponsor and clinical center of this investigator-initiated open-label single center single-arm, exploratory phase II study. The individualized treatment concept is determined to be biopsy-mandated and biomarker-based. Bio-data analysis will be supported by a software, which is generated by the Center of Medical Statistics, Informatics and Intelligent Systems.
Study design and methodology Patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma harboring an activating genetic alteration (gene mutation, gene fusion) or drug-able biomarker / activated signal transduction pathway and resistant to any approved treatment modality will be eligible for this study.
The investigators aim to combine DNA sequencing-based molecular profiling with an ex vivo high-throughput drug screening strategy. For the latter method, viable cells are obtained from the individual patient's lymphoma or leukemia in order to determine i)the expression of relevant therapeutic target molecules and ii)the ex vivo response of the patient's cancer cells to a panel of agents with anticancer activity. In addition, analysis of tumor stroma cells will provide information about the differential target expression and cellular sensitivity aiming at the evaluation of a therapeutic safety window. Thereby, biological material will have to be accessed within 4 weeks before onset of individualized treatment (real-time biopsy). Bioinformatic data-management based on a Bayesian statistical approach will support individualized treatment decisions in this controlled clinical approach.
Number of patients. A sample size of 49 patients achieves ≥ 80% power to detect a difference of 15% between the null hypothesis proportion P0 (PFS ratio ≥ 1.3) = 10% and the alternative proportion P1(PFS ratio ≥ 1.3) = 25% using a one-sided exact binomial test at a significance level of 0.0250. The null hypothesis can be rejected, if at least 10 out of 50 patients treated show a PFS ratio ≥ 1.3. The investigators therefore aim to enroll 49 leukemia patients and 49 lymphoma patients.
Target population. Patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma after standard treatment. Standard treatment is defined according to actual National Comprehensive Cancer Network (NCCN) (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp) and/or local guidelines. 49 acute leukemia subjects and 49 lymphoma subjects will be screened for enrolment in the trial. Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential. Inclusion criteria as well as exclusion criteria must be respected.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Vienna、オーストリア、1090
- Medical University Vienna
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- There are no further standard treatments available for the patient;
- The patient has undergone at least two lines of previous therapy;
- Cancer cell-containing biopsies are obtainable;
- Informed consent from the patient was given;
- candidate treatments identified by ngFDS are clinically available and considered safe given the patient health state.
Exclusion Criteria:
- Presence of further treatment options, as defined by NCCN guidelines or Austrian guidelines representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence.
- No fresh and viable tumor material available.
- Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia.
- Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
- A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
- A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
- Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol.
- Pregnant or lactating females.
- History of alcohol or drug abuse within 6 months prior to screening.
- No informed consent available.
- Exclusion criteria effective for respective treatment agents.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
ngFDS selected treatment
Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
|
Treatment based on next-generation functional drug screening (ngFDS).
Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening.
For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
progression-free survival
時間枠：From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
To compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on.
The treatment concept is deemed for clinical benefit for the individual patient who has a PSF ratio (PSF on molecular profiling-based therapy/PSF on prior therapy) of ≥ 1.3.
For this purpose we will reject the null hypothesis, which is defined as follows: ≤ 15% of patients would have a PFS ratio of ≥ 1.3.
Thus, the individual patient is his own control.
For tumor types with high numbers of patients per cohort, the overall response rate (ORR) will be evaluated.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
overall response rate
時間枠：4 months
|
overall response rate (ORR: achieving either CR or PR).
For lymphoma patients' responses were classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the criteria proposed by the International Workshop for malignant lymphoma.
For leukemia patients, responses were assessed following the response criteria defined by the recommendations of the European Leukemia net.
|
4 months
|
協力者と研究者
捜査官
- 主任研究者：Philipp B Staber, MD, PhD、Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。